Try our beta test site
14 studies found for:    indoximod
Show Display Options
Rank Status Study
1 Terminated IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer;   Lung Cancer;   Melanoma;   Pancreatic Cancer;   Solid Tumors
Intervention: Drug: 1-methyl-D-tryptophan
2 Active, not recruiting Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Interventions: Biological: Indoximod;   Biological: Sipuleucel-T;   Other: Placebo
3 Recruiting A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Idarubicin;   Drug: Cytarabine;   Drug: Indoximod;   Other: Placebo
4 Recruiting Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma
Interventions: Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation
5 Recruiting Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Metastatic Pancreatic Cancer
Interventions: Drug: Nab-Paclitaxel;   Drug: Gemcitabine;   Drug: Indoximod
6 Completed 1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: 1-methyl-d-tryptophan;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Active, not recruiting
Has Results
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: adenovirus-p53 transduced dendritic cell (DC) vaccine;   Drug: 1-methyl-d-tryptophan;   Other: Laboratory biomarker analysis
8 Recruiting Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab;   Drug: Nivolumab;   Drug: Pembrolizumab
9 Active, not recruiting Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Docetaxel;   Other: Placebo;   Drug: Indoximod;   Drug: Paclitaxel
10 Completed 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: 1-methyl-d-tryptophan;   Drug: docetaxel;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
11 Recruiting Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: Tergenpumatucel-L;   Drug: Indoximod 600mg;   Drug: Indoximod 1200mg
12 Recruiting Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor
Interventions: Drug: Indoximod;   Drug: Temozolomide;   Drug: Bevacizumab;   Radiation: Stereotactic Radiation
13 Withdrawn C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Adenovirus-p53 transduced dendritic cell vaccine;   Drug: 1-methyl-D-tryptophan;   Radiation: Carbon C 11 alpha-methyltryptophan
14 Recruiting Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen
Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: Tamoxifen

Study has passed its completion date and status has not been verified in more than two years.